Surface Oncology, an immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced details about its plan to initiate a randomized Phase II clinical study evaluating SRF388, in combination with Roche’s atezolizumab and bevacizumab, in patients with treatment-naïve hepatocellular carcinoma.
[Surface Oncology]
7992332
{7992332:nan}
apa
50
1
167573
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
